Evidence mapPaperPMID 39107960Full record

ArticleCNS neuroscience & therapeutics2024

S100A9 deletion in microglia/macrophages ameliorates brain injury through the STAT6/PPARγ pathway in ischemic stroke.

Xi Liu, Junmin Wang, Jian Jin, Qiongqiong Hu, Ting Zhao, Jian Wang, Jianbo Gao, Jiang Man

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Autophagy activation by the Becn1Brain, behavior, and immunity · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xi LiuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Junmin WangDepartment of Human Anatomy, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Jian JinMRI imaging core, Medical Research Center, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qiongqiong HuDepartment of Neurology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Ting ZhaoDepartment of Neurology, People's Hospital of Zhengzhou University, Zhengzhou, China.
Jian WangDepartment of Human Anatomy, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.ORCID 0000-0003-2291-640X
Jianbo GaoDepartment of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiang ManDepartment of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

Key Scientific Research Project of Universities in Henan Province 22B320013State-sponsored Postdoctoral Researcher Program GZC20232415
6 · The paper itself

Abstract

backgroundMicroglia and infiltrated macrophages (M/M) are integral components of the innate immune system that play a critical role in facilitating brain repair after ischemic stroke (IS) by clearing cell debris. Novel therapeutic strategies for IS therapy involve modulating M/M phenotype shifting. This study aims to elucidate the pivotal role of S100A9 in M/M and its downstream STAT6/PPARγ signaling pathway in neuroinflammation and phagocytosis after IS.

methodsIn the clinical study, we initially detected the expression pattern of S100A9 in monocytes from patients with acute IS and investigated its association with the long-term prognosis. In the in vivo study, we generated the S100A9 conditional knockout (CKO) mice and compared the stroke outcomes with the control group. We further tested the S100A9-specific inhibitor paqunimod (PQD), for its pharmaceutical effects on stroke outcomes. Transcriptomics and in vitro studies were adopted to explore the mechanism of S100A9 in modulating the M/M phenotype, which involves the regulation of the STAT6/PPARγ signaling pathway.

resultsS100A9 was predominantly expressed in classical monocytes and was correlated with unfavorable outcomes in patients of IS. S100A9 CKO mitigated infarction volume and white matter injury, enhanced cerebral blood flow and functional recovery, and prompted anti-inflammation phenotype and efferocytosis after tMCAO. The STAT6/PPARγ pathway, an essential signaling cascade involved in immune response and inflammation, might be the downstream target mediated by S100A9 deletion, as evidenced by the STAT6 phosphorylation inhibitor AS1517499 abolishing the beneficial effect of S100A9 inhibition in tMCAO mice and cell lines. Moreover, S100A9 inhibition by PQD treatment protected against neuronal death in vitro and brain injuries in vivo.

conclusionThis study provides evidence for the first time that S100A9 in classical monocytes could potentially be a biomarker for predicting IS prognosis and reveals a novel therapeutic strategy for IS. By demonstrating that S100A9-mediated M/M polarization and phagocytosis can be reversed by S100A9 inhibition in a STAT6/PPARγ pathway-dependent manner, this study opens up new avenues for drug development in the field.

Indexed as

Calgranulin BIschemic StrokeMacrophagesMice, KnockoutMicrogliaPPAR gammaSignal TransductionSTAT6 Transcription FactorAgedAnimalsFemaleHumansMaleMiceMice, Inbred C57BLMiddle AgedCalgranulin BPPAR gammaS100A9 protein, humanS100A9 protein, mouseSTAT6 protein, humanStat6 protein, mouseSTAT6 Transcription Factorischemic strokemacrophagemicroglianeuroinflammationphagocytosisS100A9

Identifiers

PMID39107960
PMCPMC11303267

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.